Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study of Nivolumab and Ipilimumab With and Without EXL01 in First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC)

NCT07128680 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07128680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07128680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study of Nivolumab and Ipilimumab With and Without EXL01 in First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC)
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
March 23, 2026
Completion date
August 25, 2028
Enrollment
33 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced clear cell renal cell carcinoma, advanced sarcomatoid renal cell carcinoma, metastatic clear cell renal cell carcinoma, metastatic sarcomatoid renal cell carcinoma, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8